Toronto Dominion Bank purchased a new position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 750,000 shares of the company's stock, valued at approximately $1,770,000. Toronto Dominion Bank owned approximately 1.41% of Milestone Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently bought and sold shares of MIST. Jones Financial Companies Lllp boosted its stake in Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after acquiring an additional 10,000 shares during the period. National Bank of Canada FI boosted its stake in Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after purchasing an additional 11,600 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at $73,000. XTX Topco Ltd acquired a new stake in Milestone Pharmaceuticals in the 4th quarter valued at about $80,000. Finally, Northern Trust Corp boosted its stake in shares of Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after acquiring an additional 30,772 shares in the last quarter. Institutional investors own 86.18% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on MIST shares. TD Cowen lowered Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. Cowen downgraded shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, TD Securities downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $17.00.
View Our Latest Research Report on MIST
Milestone Pharmaceuticals Stock Performance
Shares of Milestone Pharmaceuticals stock traded down $0.12 during midday trading on Tuesday, hitting $1.42. The company had a trading volume of 1,792,751 shares, compared to its average volume of 905,237. The business's 50 day simple moving average is $1.18 and its two-hundred day simple moving average is $1.70. The stock has a market cap of $75.92 million, a PE ratio of -1.75 and a beta of 0.86. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. Milestone Pharmaceuticals Inc. has a 1-year low of $0.63 and a 1-year high of $2.75.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.12). As a group, equities analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.
About Milestone Pharmaceuticals
(
Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Featured Stories
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
